Overview

A Study of Baricitinib and Simvastatin in Healthy Participants

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to determine the effects of baricitinib on the time it takes to remove simvastatin from the body and to look at how well-tolerated and safe baricitinib is when given alone and in combination with simvastatin. Side effects will be documented. The study will last approximately 7 days from the first dose to the end of the study (not including screening or follow-up).
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Simvastatin